Our Blog
PANTHERx Closes 2020 with Another #1 Patient Satisfaction Victory
March 10, 2021
PANTHERx Rare Pharmacy is proud to have again earned the #1 ranking in the quarterly patient satisfaction survey conducted by MMIT, an independent national survey entity. For the fourth quarter of 2020, PANTHERx obtained the highest Net Promoter Score (NPS) among all pharmacies surveyed. Net Promoter Score (NPS) is compiled by asking patients, on a […]
PANTHERx Rare Recognized In Top 10 Specialty Pharmacies of 2019
April 28, 2020
PANTHERx Rare Pharmacy earns a spot on exclusive list as a Top 10 Specialty Pharmacy of 2019 as reported by Adam Fein, Ph.D., CEO of Drug Channels Institute. The list, based on specialty drug dispensing revenues, includes PBM-owned, hospital-owned, and independent specialty pharmacies. “As the largest independent specialty pharmacy, PANTHERx Rare is proud to have […]
The Emergence and Reemergence of Specialty Pharmacy: JMCP Recounts a Father’s Prescient of the Specialty Pharmacy Industry and His Son’s Perspective 20 Years Later
March 2, 2020
This year, the highly respected Journal of Managed Care & Specialty Pharmacy (JMCP) celebrates its 25th anniversary. To mark this milestone, they are publishing a series of landmark articles documenting the changes to the specialty pharmacy industry since the journal began publishing in 1995. This month the featured pairing highlights the state, growth, and challenges […]
PANTHERx Closes 2019 with Another Consecutive #1 Patient Satisfaction Victory
February 28, 2020
PANTHERx Rare Pharmacy is proud to have again earned the #1 ranking in the quarterly patient satisfaction survey conducted by Zitter Health Insights, an independent national survey entity. For the fourth quarter of 2019, PANTHERx obtained the highest Net Promoter Score (NPS) among all independent specialty pharmacies surveyed. Net Promoter Score (NPS) is compiled by […]
Consistent Rise in Orphan Drug Approvals Brings Doses of Hope to the Rare Disease Community
January 8, 2020
The end of the decade brought with it an exciting and critical trend for people living with rare diseases. Over the last eight years, the Center for Drug Evaluation and Research (CDER) approved more than twice as many orphan drugs as in the previous eight years (see graph below). It is often the case that […]